Prevention and management of medication overuse headache

Current Opinion in Neurology

Volumn 25, Issue 3, 2012, Pages 290-295

  Russell, Michael Bjørn ^a,b   Lundqvist, Christofer ^a,b,c  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c Research Centre   (Norway)

Author keywords

Headache; Medication overuse; Severity dependence score; Short advice and withdrawal

Indexed keywords

ANALGESIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BOTULINUM TOXIN A; ERGOTAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; TOPIRAMATE; TRANQUILIZER; TRIPTAN DERIVATIVE;

COGNITIVE THERAPY; COST OF ILLNESS; DISEASE DURATION; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG INDUCED HEADACHE; DRUG USE; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; IMMOBILIZATION; INCIDENCE; MUSCULOSKELETAL DISEASE; PATIENT COUNSELING; PATIENT EDUCATION; PHYSICIAN; PREDICTIVE VALUE; PREVALENCE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SMOKING; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANALGESICS; COGNITIVE THERAPY; DISEASE MANAGEMENT; HEADACHE DISORDERS, SECONDARY; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SUBSTANCE-RELATED DISORDERS;

EID: 84860708712     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328352c431     Document Type: Review

References (34)

1. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd ed. Cephalalgia 2004; 24 (Suppl 1):9-160.
2. Silberstein SD, Olesen J, BousserMG, et al. The International Classification of Headache Disorders, 2nd Edition (ICHD-II)-revision of criteria for 8.2 Medication-overuse headache. Cephalalgia 2005; 25:460-465.
3. Grande RB, Aaseth K, Gulbrandsen P, et al. Prevalence of primary chronic headache in a population-based sample of 30-to 44-year-old persons. The Akershus study of chronic headache. Neuroepidemiology 2008; 30:76-83.
4. Aaseth K, Grande RB, Kvaerner KJ, et al. Prevalence of secondary chronic headaches in a population-based sample of 30-44-year-old persons. The Akershus study of chronic headache. Cephalalgia 2008; 28:705-713.
5. Jensen R, Stovner LJ. Epidemiology and comorbidity of headache. Lancet Neurol 2008; 7:354-361.
6. Rasmussen BK, Jensen R, Olesen J. Impact of headache on sickness absence and utilisation of medical services: a Danish population study. J Epidemiol Commun Health 1992; 46:443-446.
7. Berg J, Stovner LJ. Cost of migraine and other headaches in Europe. Eur J Neurol 2005; 12 (Suppl 1):59-62.
8. Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999; 159:813-818.
9. Andlin-Sobocki P, Jö nsson B, Wittchen HU, Olesen J. Cost of disorders in the brain in Europe. Eur J Neurol 2005; 12:1-27.
10. Hagen K, Linde M, Steiner TJ, et al. Risk factors for medication-overuse headache: An 11-year follow-up study. The Nord-Trøndelag Health Studies. Pain 2012; 153:56-61.
11. Lauwerier E, Paemeleire K, Van Damme S, et al. Medication use in patients with migraine and medication-overuse headache: the role of problem-solving and attitudes about pain medication. Pain 2011; 152:1334-1339.
12. Fritsche G, Frettlöh J, Hüppe M, et al. Prevention of medication overuse in patients with migraine. Pain 2010; 151:404-413.
13. Fuh JL, Wang SJ, Lu SR, Juang KD. Does medication overuse headache represent a behavior of dependence? Pain 2005; 119:49-55.
14. Radat F, Creach C, Guegan-Massardier E, et al. Behavioral dependence in patients with medication overuse headache: a cross-sectional study in consulting patients using the DSM-IV criteria. Headache 2008; 48:1026-1036.
15. Calabresi P, Cupini LM. Medication-overuse headache: similarities with drug addiction. Trends Pharmacol Sci 2005; 26:62-68.
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington: American Psychiatric Association, 1994.
17. Gossop M, Darke S, Griffiths P, et al. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 1995; 90:607-614.
18. Grande RB, Aaseth K, Saltyte Benth J, et al. The Severity of Dependence Scale detects people with medication overuse: the Akershus study of chronic headache. J Neurol Neurosurg Psychiatry 2009; 80:784-789.
19. Lundqvist C, Aaseth K, Grande RB, et al. The Severity of Dependence Score correlates with medication overuse in persons with secondary chronic headaches. The Akershus study of chronic headache. Pain 2010; 148:487-491.
20. Lundqvist C, Benth JŠ, Grande RB, et al. An adapted Severity of Dependence Scale is valid for the detection of medication overuse: the Akershus study of chronic headache. Eur J Neurol 2011; 18:512-518.
21. Lundqvist C, Grande RB, Aaseth K, Russell MB. Dependence scores predict prognosis of medication overuse headache: A prospective cohort from the Akershus study of chronic headache. Pain 2012; 153:682-686.
22. Katsarava Z, Fritsche G, Muessig M, et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001; 57:1694-1698.
23. Grande RB, Aaseth K, Šaltyt-Bent J, et al. Reduction of medication-overuse headache after modified brief intervention. The Akershus study on chronic headache. Eur J Neurol 2011; 18:129-137.
24. Aaseth K, Grande RB, Šaltyt-Bent J, et al. 3-years-follow-up of secondary chronic headaches. The Akershus study of chronic headache. Eur J Pain 2011; 15:186-192.
25. Bigal ME, Rapoport AM, Sheftell FD, et al. Transformed migraine and medication overuse in a tertiary headache centre: clinical characteristics and treatment outcomes. Cephalalgia 2004; 24:483-490.
26. Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia 2006; 26:1192-1198.
27. Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27:814-823.
28. Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatmentof chronic migraine: a randomized, double-blind, placebocontrolled trial. Headache 2007; 47:170-180.
29. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebocontrolled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30:793-803.
30. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebocontrolled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30:804-814.
31. Headache Classification Committee, Olesen J, Bousser MG et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26:742-746.
32. Olesen J, Tfelt-Hansen P. Licence for Botox in so-called chronic migraine. Lancet 2010; 376:1825-1826.
33. Relja M, Poole AC, Schoenen J, et al. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinumtoxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 2007; 27:492-503.
34. Silberstein SD, Gö bel H, Jensen R, et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 2006; 26:790-800.